Edesa Biotech, Inc. (EDSA)
Largest Insider Buys in Sector
EDSA Stock Price History Chart
EDSA Stock Performance
About Edesa Biotech, Inc.
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Insider Activity of Edesa Biotech, Inc.
Over the last 12 months, insiders at Edesa Biotech, Inc. have bought $20,000 and sold $0 worth of Edesa Biotech, Inc. stock.
On average, over the past 5 years, insiders at Edesa Biotech, Inc. have bought $65,600 and sold $416,206 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Nijhawan Pardeep (Chief Executive Officer) — $20,000.
The last purchase of 5,000 shares for transaction amount of $20,000 was made by Nijhawan Pardeep (Chief Executive Officer) on 2024‑03‑25.
List of Insider Buy and Sell Transactions, Edesa Biotech, Inc.
| 2024-03-25 | Chief Executive Officer | 5,000 0.1509% | $4.00 | $20,000 | +4.31% | |||
| 2023-01-10 | Sale | director | 152,345 0.8038% | $2.63 | $401,368 | -30.36% | ||
| 2023-01-09 | Sale | director | 145,129 0.7355% | $2.66 | $386,348 | -30.36% | ||
| 2022-06-30 | Chief Executive Officer | 20,000 0.165% | $1.60 | $32,078 | -29.19% | |||
| 2022-06-29 | President | 3,000 0.0196% | $1.49 | $4,483 | -22.30% | |||
| 2022-06-16 | President | 3,000 0.0189% | $1.61 | $4,817 | -24.24% | |||
| 2022-05-27 | Chief Executive Officer | 5,000 0.0317% | $1.92 | $9,599 | -28.57% | |||
| 2022-05-25 | President | 3,500 0.0226% | $1.74 | $6,090 | -19.54% | |||
| 2022-05-24 | Chief Executive Officer | 2,000 0.0133% | $1.80 | $3,600 | -19.43% | |||
| 2022-03-31 | Chief Executive Officer | 2,000 0.013% | $2.99 | $5,972 | -45.45% | |||
| 2022-03-30 | Chief Executive Officer | 2,000 0.0148% | $3.05 | $6,098 | -45.30% | |||
| 2022-03-29 | Chief Executive Officer | 2,000 0.0147% | $3.02 | $6,034 | -44.75% | |||
| 2022-03-18 | Chief Executive Officer | 2,000 0.0138% | $3.85 | $7,699 | -58.48% | |||
| 2022-03-17 | Chief Executive Officer | 397 0.0027% | $3.25 | $1,290 | -50.74% | |||
| 2022-03-15 | Chief Executive Officer | 2,000 0.0131% | $2.80 | $5,598 | -45.63% | |||
| 2022-03-14 | President | 1,250 0.0092% | $2.79 | $3,487 | -37.87% | |||
| 2022-03-11 | Chief Executive Officer | 5,000 0.0368% | $3.06 | $15,295 | -43.67% | |||
| 2022-03-10 | President | 1,000 0.0074% | $3.22 | $3,223 | -46.35% | |||
| 2022-03-09 | Chief Executive Officer | 1,500 0.0103% | $3.05 | $4,570 | -46.71% | |||
| 2022-03-08 | President | 1,250 0.0091% | $2.90 | $3,622 | -40.56% |